Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
Phase 1/2 study testing AMT-130 in Huntington's disease.
Active, not recruitingPhase 1 / Phase 2GeneticClinicalTrials.govTreatment trial
Recruiting in: Cardiff, London, Warsaw (Poland, United Kingdom)
Sponsor: UniQure Biopharma B.V.
Preparing a short plain-English summary.